Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study
复制标题
DOI：
10.1038/sj.bjc.6605799
复制
发表时间：
2010-08-10
影响因子：
8.8
通讯作者：
Thompson, A. M.
中科院分区：
文献类型：
--
作者：
Purdie, C. A.;Baker, L.;Thompson, A. M.
背景：本研究评估了未选择的未接受 HER2 靶向治疗的乳腺癌患者群体中人表皮生长因子受体 2 (HER2) 状态对结果的影响。方法：通过免疫组织化学和荧光原位杂交将 HER2 状态与所有 3 年以上乳腺癌患者的临床病理数据、总生存期 (OS) 和无病生存期 (DFS) 进行比较。结果：在 865 名患者中（中位随访 6.02 年），13.3% 的癌症中发现 HER2 阳性，并且与较高的肿瘤分级相关（P
BACKGROUND: This study assessed the impact of human epidermal growth factor receptor 2 (HER2) status on the outcomes in an unselected population of breast cancer patients who did not receive HER2-targeted therapy.METHODS: HER2 status by immunohistochemistry and fluorescence in situ hybridisation was compared with clinicopathological data, overall survival (OS) and disease-free survival (DFS) for all patients presenting with breast cancer over 3 years.RESULTS: In 865 patients (median follow up 6.02 years), HER2 positivity was identified in 13.3% of all cancers and was associated with higher tumour grade (P